Objective: We used magnetic resonance (MR) imaging and hormonal levels to evaluate the influence of chemotherapy for cervical cancer on female pelvic reproductive organs.
Introduction
Various cancers occur in women of reproductive age, but the most frequent malignancies in women under age 40 are breast cancer, cervical cancer, sarcoma, and non-Hodgkin's lymphoma. 1 Impairment of fertility in varying degrees by chemotherapy has made preservation of fertility in patients with cancer a challenging problem in recent years. 2 Such impairment is believed to result from ovarian toxicity.
The pathogenesis of chemotherapy-induced ovarian toxicity involves direct ovarian toxicity, reduction in ovarian blood flow caused by acute vascular insult, and oxidative stress, which differ depending on the type of chemotherapeutic agents utilized. 1 Chemotherapy-induced ovarian toxicity can cause such symptoms as irregular menses, chemotherapyrelated amenorrhea, and infertility, which ultimately lead to premature ovarian failure (POF). These conditions can lead to profound physical and emotional consequences and diminish quality of life. [3] [4] [5] Ultrasonographic (US) assessment of the antral follicle count (AFC) and ovarian volume are used to assess ovarian reservation after chemotherapy. 6, 7 More particularly, it is generally considered that the AFC can provide reliable assessment of a patient's fertility status and risk of POF. To the best of our knowledge, no report has described the use of MR imaging of the female reproductive organs following chemotherapeutic treatment. The excellent characterization of tissue by MR imaging reflects pathological conditions, and changes in the appearance of female reproductive organs on MR imaging due to hormonal changes, such as those of menopause or following treatment with gonadotropin-releasing hormone (GnRH) analog have been described. 8 -10 We investigated whether we could visualize the effects of chemotherapy-induced ovarian toxicity on the female reproductive organs using MR imaging. We speculated that MR imaging would be a valuable tool in addition to US for the visualization of such toxicity of chemotherapy for fertility, assessment of fertility status, and prediction of premature ovarian failure.
We analyzed the effects of chemotherapy on the female reproductive organs using MR imaging, aiming to assess morphological changes in the uterus and ovaries in patients with uterine cervical cancer who had undergone neoadjuvant chemotherapy (NACT) and to compare findings between pre-and postmenopausal patients.
Materials and Methods
Our institutional review board approved the study, and we obtained patient consent.
Between May 1, 2009 and November 30, 2012, 33 patients with squamous cell carcinoma of the uterine cervix in clinical Stages IB2 to IIB (International Federation of Gynecology and Obstetrics classification) underwent 2 courses of NACT followed by radical hysterectomy. All cases were diagnosed as squamous cell carcinoma by biopsy diagnosed by an experienced pathologist and clinically staged by experienced gynecological oncologists.
Of the 33 patients, we included in the study patients who underwent MR studies both before and after NACT. We excluded 6 patients-three with incomplete MR study sets, one who did not complete NACT as a result of disease progression after the first course of NACT, one with massive myometrial invasion that impeded clinical evaluation of the uterine body, and one who received GnRH during chemotherapy to preserve ovarian function with the intention of radical trachelectomy. Thus, our study finally included 27 patients (aged 30 to 69 years, mean age, 50.7). None had a history of other malignant tumor.
We divided patients into pre-and postmenopausal groups, with menopause defined as amenorrhea longer than 12 months. 7 MR imaging scanning protocol MR imaging studies were performed using a 3.0-tesla (Skyla µ or Trio; Siemens AG, Erlangen, Germany) or 1.5T (Avanto µ ; Siemens AG, Erlangen, Germany) machine. The protocols included axial T 2 -weighted images (WI), oblique axial T 2 -WI, and sagittal T 1 -and T 2 -WI. The sequences used to evaluate changes in the uterine body and ovaries were axial, oblique axial, and sagittal T 2 -WI. For the axial spin-echo T 2 -WI sequence, parameters were: repetition time (TR)/echo time (TE) 4500/81 ms; flip angle (FA), 150°; bandwidth, 250; slice thickness, 4 mm; intersection gap, one mm; matrix, 512 © 512; and field of view (FOV), 320 © 320 mm. For the oblique axial spin-echo T 2 -WI sequence, parameters were: TR/TE 4500/81 ms; FA, 150°; bandwidth 254; slice thickness, 3 mm; intersection gap, 0.48 mm; matrix, 448 © 314; and FOV, 100 © 70 mm. For the sagittal spin-echo T 2 -WI sequence, parameters were: TR/TE, 4500/81 ms; FA, 150°; bandwidth, 370; slice thickness, 4 mm; intersection gap, one mm; matrix, 448 © 328; and FOV, 260 © 190 mm.
Hyoscine butylbromide (Buscopan µ ; Boehringer Ingelheim, Ingelheim am Rhein, Germany) was administered intramuscularly (20 mg) before image acquisition to reduce bowel motion unless there was a contraindication or consent was not obtained. The time period between pretreatment and post-NACT MR imaging ranged from 35 to 63 days (mean, 52 days).
Imaging evaluation
For quantitative analysis, one radiologist, a specialist in gynecological imaging with 5-years' experience, used pre-and post-NACT MR studies to measure the volume of the uterine body and bilateral ovaries, thickness of the endometrium, and signal intensity (SI) ratio of the myometrium and of the bilateral ovarian tissue in both the pre-and postmenopausal groups. The volumes of uterine body and bilateral ovaries were calculated using sagittal and axial T 2 -WI and the ellipsoid formula, (L1 © L2 © L3)³/6, where L1 is the maximal transverse length, L2 is the maximal anteroposterior length, and L3 is the maximal longitudinal length. The uterus with leiomyomas was also measured in a similar manner (n = 3). The thickness of the endometrium was measured on the sagittal maximum cross-section of T 2 -WI. SI ratios of the anterior and posterior myometrium and of the bilateral ovarian tissue were normalized by the SI of the gluteus maximus muscle. The SI of the uterine myometrium was measured on the sagittal maximum cross-section of T 2 -WI, avoiding the junctional zone (JZ) and uterine leiomyoma. The SI of ovarian tissues was measured on the axial or oblique axial maximum cross-section of T 2 -WI, avoiding follicles or functional cysts. Each value was measured in a manually placed circular region of intensity (ROI) that measured approximately 20 mm 2 for the uterus and ovarian tissues and 100 mm 2 for the gluteus maximus muscle. In a qualitative analysis, we evaluated visualization of the JZ of the uterine myometrium as well as the follicles of the bilateral ovaries in both pre-and post-NACT MR studies. We evaluated the JZ on sagittal T 2 -WI and the bilateral follicles on axial and oblique axial T 2 -WI. Two independent radiologists specialized in gynecological imaging, with 5 and 16 years' experience, determined whether these structures were visible and resolved differing evaluation results by consensus.
Hormonal levels
Hormonal levels of estradiol (E 2 ), progesterone, follicle-stimulating hormone (FSH), and luteinizing hormone (LH) before NACT and after completion of NACT were available in 8 pre-and 4 postmenopausal patients. In premenopausal patients, we evaluated the changes in each hormone between preand post-NACT. In postmenopausal patients, we did not perform the analysis because the number of patients with available pairs of data was too small (n = 4). In one premenopausal patient (age 51 years), the E 2 value was undetectable (<5.0 pg/mL) in the pre-and post-NACT studies, so 1.0 pg/mL was used as a substitute value.
Statistical analysis
Statistical analysis of the quantitative and qualitative factors (pre-versus post-NACT comparison) was conducted using Student's t-test
We analyzed pre-and post-NACT hormonal values using Student's t-test in premenopausal patients. In all analyses, P < 0.05 was considered statistically significant.
Results
One patient had a serous adenofibroma of the left ovary, thus data obtained from this left ovary were excluded from the study. In another patient (62 years old) from the post-menopausal group, the bilateral ovaries were undetectable in both pre-and post-NACT MR imaging. In total, we evaluated 27 uterine bodies and 51 ovaries. Tables 1 and 2 present the MR imaging results with P-values of the preand post-menopausal groups.
In the premenopausal group, all assessed values, including the volume of the uterine body and of bilateral ovaries, thickness of the endometrium, and SI ratios of the anterior and posterior uterine myometrium and of the ovaries, were significantly decreased after NACT (Table 1A, Figs. 1, 2) . In the postmenopausal patients, endometrial thickness was significantly decreased (P < 0.05). Other parameters tested for quantitative evaluation did not differ significantly, though the volume of the right ovary tended to decrease (P = 0.06) (Table 1B, Fig. 3 ).
Regarding the qualitative evaluation, the number of left ovaries with visible follicles decreased significantly after NACT in the premenopausal group (P < 0.05, Table 2A ). Changes in recognition of the JZ and right follicles in the premenopausal group did not differ significantly (P = 0.12, 0.06), but the structures tended to disappear after chemotherapy. In the postmenopausal group, there was no statistical significance in any of the qualitative items (Table 2B). Table 3 lists the means and ranges of hormone values in the pre-and post-NACT studies for the premenopausal group. The levels of progesterone, FSH, and LH decreased after NACT, and this was statistically significant (P < 0.05) in all cases. E 2 levels tended to decrease, but not significantly (P = 0.05). As described above, we did not analyze hormonal values in postmenopausal patients. The range in levels of E 2 (below the detection threshold to 11.0 pg/mL), progesterone (below the detection threshold to 0.28 ng/mL), FSH (51.3 to 91.9 mIU/ mL), and LH (24.7 to 37.2 mIU/mL) of postmenopausal patients were all consistent with those levels in postmenopausal women.
Discussion
In premenopausal patients, we observed a statistically significant decrease in all quantitative parameters as well as in the visibility of the follicles in the left ovary. The visibility of the follicles in the right ovary also tended to decrease (P = 0.06), but results were not statistically significant. On the other hand, we detected no significant changes in postmenopausal patients, except for the endometrial thickness.
The variations observed in premenopausal patients may be due to the ovarian toxicity of chemotherapy and to the secondary hormonal changes observed in the study. 1, [9] [10] [11] [12] [13] [14] [15] The changes observed in the MR appearance of ovaries in premenopausal patients, (i.e., decreased volume of the ovaries, intensity of ovarian tissues on T 2 -WI, and visualization of the follicles), could be explained by the ovarian toxicity induced by NACT. This toxicity might be primarily caused by the platinum-based compound. 1, 13, 16 Evidence of ovarian toxicity induced by a platinum-based compound has been published with regard to CDDP only, which was used in one patient in our study. The mechanisms of ovarian toxicity caused by CDDP entail destruction of primordial follicles and oocyte death. 1 The toxicity of CPT-11, a plant alkaloid, remains controversial. Tanaka's team reported a strong ovarian toxicity of CPT-11, 17 but Meirow and colleagues reported no increased risk of ovarian failure in patients treated with plant alkaloids. 1, 13 Histologic findings associated with chemotherapy include ovarian atrophy, reduced numbers of follicles, diminished ovarian weight, and stromal fibrosis.
14,15 Morphological changes in the MR imaging appearance of ovaries after NACT in premenopausal patients were expected to reflect these pathological conditions. Lower SI of the ovarian tissue after chemotherapy might reflect fibrosis of the ovarian stromal tissue. Decrease in the ovarian volume might represent the atrophy itself. The tendency of the bilateral follicles to disappear after NACT could reflect depletion of the follicles, although this was not statistically significant in the right ovary. The magnitude of ovarian failure and diminished fertility potential caused by chemotherapy varies among patients, depending on the patient's age at the time of treatment, type of chemotherapeutic agent used, duration of therapy, and total cumulative dose administered. 1 Severe ovarian damage might lead to chemotherapy-related amenorrhea, infertility, and, ultimately, POF. 4, 18 In the pretreatment MR imaging studies of the postmenopausal group, follicles of the right ovaries were still visible in 5 of 11 patients, more than were observed for the left ovaries. Follicles disappeared after NACT in 2 of the 5 patients. The tendency of the right ovaries to disappear after NACT (P = 0.06) might explain the decrease in right ovarian volume (P = 0.06). The number of follicles remaining at menopause has been reported to be below 1000. 6 Thus, the ovarian toxicity induced by chemotherapy might impair the very limited follicle stockpile and the residual ovarian function left after menopause and lead to a secondary decrease in endometrial thickness.
To the best of our knowledge, there is no evidence for chemotherapy-induced uterine toxicity. 1, 19 Changes we observed in the MR appearance of the uterus after chemotherapy in premenopausal patients included variations in the volume of uterine body, endometrial thickness, and the SI ratio of the myometrium in T 2 -WI; some of these changes would have been difficult to assess using ultrasound because of its inferior tissue contrast. These appearances are similar to those classically observed in postmenopausal subjects. Decrease in the volume of the uterine body and thickness of the endometrium have been reported in postmenopausal subjects and are explained by the decreased serum levels of estrogen and progesterone. 9, 11, 12 We suggest that the uterine changes observed in the premenopausal group might reflect morphological changes caused by the ovarian toxicity of chemotherapy and the following decreased levels of sex steroid. The combination of our MR imaging approach with comparison of surgical specimens after NACT with premenopausal organs of women of the same ages with the same conditions without NACT might provide valuable information about the practical management of chemotherapy-induced infertility.
In our study, the JZ in premenopausal patients tended to be invisible after NACT, though the difference between visualization before and after was not significant. Obscuration of the JZ has been reported as a postmenopausal change resulting from progressive dehydration and fibrous involution of the outer myometrium. 10 This might also explain the reduced recognition of the JZ in our study; the JZ remained visible in 12 of 16 premenopausal patients after chemotherapy, although the hormonal status was similar to that of a postmenopausal state. The differences in visualization of the JZ between postmenopausal women previously reported and post-chemotherapy premenopausal patients described in our study might be due to differences in the degree and duration of low hormonal levels. Postmenopausal women might have lower hormonal levels for longer periods.
Our study has several limitations. First, imaging was timed without regard for patients' menstrual cycles, which might have affected our results. However, timing of pre-and post-NACT MR imaging were influenced by clinical needs; for example, post-NACT MR imaging was intended to evaluate the efficacy of treatment. Thus, timing of imaging without knowledge of the patients' menstrual cycles was inevitable in clinical situations. Second, the number of subjects in this study was small, especially the number with available information regarding hormonal changes. Follow-up studies with a larger number of subjects with hormonal values are required. Third, we did not include findings of histological analysis. Correlation of radiological and pathological findings is desirable for the precise evaluation of chemotherapy-induced infertility, especially for evaluating the cause of decreased SI ratio of the uterine myometrium and the ovarian tissue. All our subjects were treated with NACT following surgery, so we are currently investigating the radiological-pathological correlation.
In conclusion, we used MR imaging to evaluate morphological changes in the uterus and ovaries in pre-and postmenopausal patients who had undergone NACT. In premenopausal subjects, the MR appearances of the uterus and ovaries resembled those of postmenopausal women after chemotherapy. These changes are believed to result from ovarian toxicity induced by chemotherapy and from secondary hormonal changes. Our findings provide additional information about the mechanism and practical management of chemotherapy-induced infertility. 
